RAS Inhibitors Market By Drug Class (ACE Inhibitors (Lisinopril, Enalapril, Ramipril), ARBs (Losartan, Valsartan, Candesartan), Renin Inhibitors (Telmisartan, Aliskiren, Moexipril)), By Application (Hypertension, Heart Failure, Diabetic Nephropathy, and Others), By End-Use Industry (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography - RAS Inhibitors Market

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

RAS Inhibitors Market is estimated to be valued at USD XX billion in 2022 and is poised to grow at a significant CAGR of XX% over 2023-2029. RAS inhibitors are drugs that target components of the renin-angiotensin system to regulate blood pressure and fluid balance. ACE inhibitors block the action of ACE enzymes, reducing the production of angiotensin II, a vasoconstrictor that raises blood pressure. Common ACE inhibitors include lisinopril, enalapril, and captopril. These drugs play a crucial role in managing cardiovascular and renal conditions associated with high blood pressure and heart failure. However, it's important to note that RAS inhibitors can have side effects such as hypotension, cough, and hyperkalemia. Therefore, their use should be monitored and guided by healthcare professionals. The global RAS inhibitors market is driven by the increasing prevalence of cardiovascular diseases (CVDs), which are the leading cause of death worldwide. RAS-acting agents are commonly used to treat hypertension and heart failure, major risk factors for CVDs. Ongoing research exploring their potential use in other conditions, like kidney disease, also contributes to market growth. The availability of generic versions of these drugs is making treatment more affordable and accessible. However, the market faces competition from alternative treatments and potential side effects associated with RAS-acting agents. Overall, the market is driven by the need to address the growing burden of CVDs and improve patient outcomes.

RAS Inhibitors Market Key Developments:
In November 2021, Boehringer Ingelheim announced the launch of a new fixed-dose combination product containing telmisartan and amlodipine besylate for the treatment of hypertension. The product, called Twynsta Duo, is now available in the U.S.

RAS Inhibitors Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
RAS Inhibitors Market Dynamics

One key driver of the global RAS inhibitors market is the growing trend toward combination therapies. Combination therapy involves using multiple drugs together to achieve more effective treatment outcomes. This approach is increasingly being adopted in the management of cardiovascular diseases and renal disorders, as it offers improved effectiveness, minimized side effects, and enhanced patient adherence. RAS inhibitors, when used in combination with other medications like diuretics, beta-blockers, and calcium channel blockers, have demonstrated promising results in reducing blood pressure and addressing heart failure. The rising adoption of combination therapies is anticipated to fuel the demand for RAS inhibitors in the forecasted future.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

RAS Inhibitors Market Segmentation

By Drugs Class
  • ACE Inhibitors 
  • Renin Inhibitors 
By Application
  • Hypertension
  • Heart Failure
  • Diabetic Nephropathy
  • Others
By End-Use
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America

Frequently Asked Questions

RAS inhibitors, also known as renin-angiotensin system inhibitors, are a class of drugs used to treat cardiovascular and renal disorders. They target components of the renin-angiotensin system, which regulates blood pressure and fluid balance in the body.

An increase in the prevalence of CVDs globally and continuous research and development are the prominent players in the market.

North America is estimated to be a prominent region during the forecast period.

  • Novartis AG
  • Pfizer, Inc.
  • AstraZeneca plc.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Other Prominent Players.